🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. Nimotuzumab

    Chinese University of Hong Kong

    Esophageal Cancer

    phase 2 small molecule completed

    1 trial

  2. Nimotuzumab combined with chemoradiotherapy

    The First People's Hospital of Lianyungang

    Pancreatic Cancer Non-resectable

    phase 2 small molecule active

    1 trial

  3. Niraparib

    Takeda

    Ovarian Cancer

    phase 2 small molecule completed

    2 trials

  4. Niraparib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  5. Niraparib

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    Platinum-resistant Recurrent Clear Cell Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  6. Niraparib-Bevacizumab

    Takeda

    Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor

    phase 2 small molecule active

    1 trial

  7. Nivolumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Biliary Tract Cancer(BTC)

    phase 2 small molecule active

    1 trial

  8. Nivolumab

    Adaptive Biotechnologies Corp

    Bladder Cancer

    phase 2 small molecule completed

    1 trial

  9. Nivolumab

    Bristol-Myers Squibb

    Prostate Cancer

    phase 2 mab completed

    1 trial

  10. Nivolumab

    Mereo BioPharma Group plc

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  11. Nivolumab & Ipilimumab

    The First People's Hospital of Lianyungang

    Lung Cancer - Non Small Cell

    phase 2 small molecule active

    1 trial

  12. OGX-011

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 2 mab completed

    1 trial

  13. OLAPARIB, BEVACIZUMAB

    The George Institute

    Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer

    phase 2 small molecule active

    1 trial

  14. OMEPRAZOLE , ACETYLSALICYLIC ACID

    The George Institute

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  15. OMP-59R5

    Mereo BioPharma Group plc

    Stage IV Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  16. OMP-59R5

    Mereo BioPharma Group plc

    Stage IV Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  17. ONO-4578

    Ono Pharmaceutical Co.,

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  18. ONO-4578, ONO-4578, BEVACIZUMAB, ONO-4578, CALCIUM FOLINATE, OXALIPLATIN, OPDIVO 10 mg/mL concentrate for solution for infusion., FLUOROURACIL

    Lacuna Pharma Pty Ltd

    PD-L1 positive advanced colorectal cancer

    phase 2 small molecule active

    1 trial

  19. OPDIVO 10 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Early stage triple negative breast cancer

    phase 2 small molecule active

    1 trial

  20. OPDIVO 10 mg/mL concentrate for solution for infusion., Anti-Fucosyl GM1 PET Tracer, ETOPOSIDE, CARBOPLATIN

    Bristol-Myers Squibb Australia Pty Ltd

    Extensive-stage Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, Ipilimumab

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or metastatic solid tumors: 1) Triple Negative Breast Cancer (TNBC) 2) Gastric Cancer (GC) 3) Pancreatic Cancer (PC) 4) Small Cell Lung Cancer (SCLC). 5) Bladder Cancer (BC) 6) Ovarian Cancer (OC)

    phase 2 small molecule active

    1 trial

  22. OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, OPDIVO 10 mg/mL concentrate for solution for infusion., DARZALEX 20 mg/mL concentrate for solution for infusion, Relatlimab, Relatlimab

    Bristol-Myers Squibb Australia Pty Ltd

    MSI Negative Colorectal Cancer, MSI Positive Colorectal Cancer

    phase 2 small molecule active

    1 trial

  23. OPDIVO 10 mg/mL concentrate for solution for infusion., Mektovi 15 mg film-coated tablets, YERVOY 5 mg/ml concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, Braftovi 75 mg hard capsules

    Ningbo Cancer Hospital

    BRAF V600 mutation–positive unresectable or metastatic melanoma

    phase 2 small molecule active

    1 trial

  24. OPDIVO 10 mg/mL concentrate for solution for infusion., Regorafenib_IJB

    The George Institute

    Locally-advanced stage II-III rectal cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources